Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AgfiledCriticalNovartis Ag
Publication of ECSP044991ApublicationCriticalpatent/ECSP044991A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Los pacientes que sufren de carcinoma renal son tratados con agentes anti-angiogénesis de 4-piridilmetil-ftalazina. Los pacientes que tienen diferentes tipos de tumor, por ejemplo, cáncer renal, son tratados con un agente anti-angiogénesis de 4-piridilmetil-ftalazina mientras experimentan quimioterapiaPatients suffering from renal carcinoma are treated with anti-angiogenesis agents of 4-pyridylmethyl-phthalazine. Patients who have different types of tumors, for example, kidney cancer, are treated with an anti-angiogenesis agent of 4-pyridylmethyl-phthalazine while undergoing chemotherapy.
ECSP0449912001-09-122004-02-27
USE OF 4-PIRIDILMETIL-FTALAZINAS FOR THE TREATMENT OF CANCER
ECSP044991A
(en)
USE OF A COMBINATION OF AN INHIBITOR OF THE KINASA OF THE RECEIVER OF THE EPIDERMAL GROWTH FACTOR AND CYTOTOXIC AGENTS FOR THE TREATMENT AND INHIBITION OF CANCER